Phase IV.II, clinical trial, with the combination of pegylated liposomal doxorubicin (Caelyx), cyclophosphamide and trastuzumab (Herceptin) in patients with metastatic breast cancer with overexpression of HER2/Neu.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cyclophosphamide; Doxorubicin liposomal; Trastuzumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 15 Jul 2019 Biomarkers information updated
- 29 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Dec 2006 Status change